SCHEMBL24077532

SCHEMBL24077532

CCOC(=O)c1cccc(NCC(=O)OC(C)(C)C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
KMT2A Q03164 2/20 0.53
TSHR P16473 1/20 0.53
RAB9A P51151 6/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
NPC1 O15118 5/20 0.52
KDM4E B2RXH2 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
CDC25B P30305 5/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 1/20 0.50
MAPK1 P28482 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7429994 0.88 CASR (0.52) ALDH1A1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL15057284 0.84 HPGD (0.48) ALDH1A1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL4490577 0.84 AKR1C3 (0.60) ALDH1A1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL4485291 0.83 PARP14 (0.47) KMT2AMEN1
SCHEMBL14435084 0.82 KMT2A (0.59) ALDH1A1KMT2ATSHRRAB9ASMN1; SMN2
SCHEMBL30353836 0.82 KMT2A (0.59) ALDH1A1KMT2ATSHRRAB9ASMN1; SMN2
SCHEMBL1543828 0.82 RAB9A (0.67) ALDH1A1KMT2ATSHRRAB9ASMN1; SMN2
SCHEMBL11088028 0.82 AKR1C3 (0.47) ALDH1A1RAB9APKMMAPTNPSR1
SCHEMBL20798155 0.81 FPR3 (0.48) ALDH1A1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL6368466 0.81 FPR3 (0.44) ALDH1A1KMT2ARAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117580831-A GRK2 inhibitors and uses thereof 索纳塔治疗公司 2024-02-20 CN disclosed
US-20230009608-A1 GRK2 INHIBITORS AND USES THEREOF SONATA THERAPEUTICS, INC. 2023-01-12 US disclosed
WO-2021242844-A1 GRK2 INHIBITORS AND USES THEREOF CYGNAL THERAPEUTICS, INC. (US) 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230009608-A1 GRK2 INHIBITORS AND USES THEREOF GRK2, GRK3, GRK1 ALDH1A1 2765/4885KMT2A 1345/4885TSHR 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.